Ola Landgren

Ola Landgren

Chief Attending Physician, Myeloma Service, Memorial Sloan-Kettering Cancer Center, USA

Dr Ola Landgren is Chief Attending of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) and Professor of Medicine at Weill Cornell Medical College. Over the past decade, he has designed and conducted a series of studies designed to define biological mechanisms of transformation from myeloma precursor disease (MGUS and smoldering myeloma) to multiple myeloma. Based on insights from these studies, he has designed and launched several early interventional clinical trials for patients with high-risk smoldering myeloma, with the aim to delay preventing transformation. Furthermore, as part of his interest in effective, non-intense therapies, he has designed clinical studies to seek rapid and deep responses. Beyond clinical criteria for complete remission, he has developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma and high-risk smoldering myeloma patients. As part of these efforts, he uses both cell-, molecular, and imaging-based methods. Dr Landgren's goal is to define sensitive MRD methods that can be used for longitudinal monitoring without the need for invasive biopsies. In his role as Chief of the Myeloma Service at MSKCC, Dr Landgren leads the clinical and research operations as well as the development of the program. He has several additional responsibilities; e.g. member of the centre MSK Scientific Review Committee (Research Council), MSKCC representative on NCI's CTEP program from myeloma, and a frequent speaker and faculty member on national and international meetings on myeloma and hematologic malignancies. Dr Landgren is on the editorial board for Haematologica and Leukemia & Lymphoma and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in the Center's research activities as either an independent investigator, as a leader of one or more research governance committees, or as part of a research team.

 

Ola Landgren is supported by Amgen's sponsorship to Blood 2018.

 

Back to speakers